Nicholas Investment Partners’s Roivant Sciences ROIV Stock Holding History

Nicholas Investment Partners’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.71M	Sell	278,425 -1,431	-0.5%	-$36.8K	0.56%	65
2025 Q4	$6.07M	Buy	279,856 +34,235	+14%	+$675K	0.44%	82
2025 Q3	$3.72M	Buy	+245,621	New	+$3.04M	0.28%	124
2024 Q1	–	Sell	-158,015	Closed	-$1.77M	–	221
2023 Q4	$1.77M	Sell	158,015 -2,840,120	-95%	-$27.7M	0.21%	142
2023 Q3	$35M	Buy	2,998,135 +732,812	+32%	+$8.28M	2.62%	5
2023 Q2	$22.8M	Buy	2,265,323 +1,192,940	+111%	+$10.7M	1.56%	21
2023 Q1	$7.91M	Buy	+1,072,383	New	+$8.83M	0.6%	48

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Nicholas Investment Partners's ROIV Position: Q1 2026 in Review

Nicholas Investment Partners reduced its Roivant Sciences (ROIV) stake by 0.51% in Q1 2026, selling an estimated $36.8K and leaving 278,425 shares worth $7.71M. The position accounts for 0.56% of the portfolio, ranked #65.

Nicholas Investment Partners first reported a position in ROIV in Q1 2023 and has held it in 7 quarters since. The position peaked at $35M in Q3 2023. 439 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

Nicholas Investment Partners held 278,425 shares of Roivant Sciences worth $7.71M as of Q1 2026.
Nicholas Investment Partners sold 1,431 Roivant Sciences shares in Q1 2026, an estimated $36.8K.
Roivant Sciences made up 0.56% of Nicholas Investment Partners's portfolio in Q1 2026, its #65 holding.
Nicholas Investment Partners first reported a position in Roivant Sciences in Q1 2023 and has held it in 7 quarters since.
Nicholas Investment Partners's Roivant Sciences position peaked at $35M in Q3 2023.
439 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on Nicholas Investment Partners's 13F filing for Q1 2026, filed 15 May 2026.